title: Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification.
abstract: OBJECTIVE
  To assess whether the sustained release of indomethacin significantly reduces postoperative inflammation and posterior capsule opacification (PCO).
  
  
  METHODS
  Nishi Eye Hospital, Jinshikai Medical Foundation, Osaka, Japan.
  
  
  METHODS
  A 7 mm diameter, 1 mm thick polylactic-polyglycolic acid disk containing 7 mg of indomethacin was implanted in five rabbit eyes after continuous curvilinear capsulorhexis and phacoemulsification. The disk and an IOL placed above it were implanted in the capsular bag. The contralateral eyes, which served as controls, received a disk without indomethacin and the same type IOL in the same manner.
  
  
  RESULTS
  The indomethacin was fully released within 3 weeks in vitro, a release rate of about 14 micrograms/h. Postoperatively, aqueous flare intensity was significantly lower at days 2, 3, and 4 and at weeks 1, 2, and 3. Prostaglandin E2 was not detectable in the aqueous humor of the indomethacin-treated eyes on day 3 and at week 4. In the control eyes, mean concentration was 491 pg/ml +/- 54 (SD) and 990 +/- 243 pg/ml, respectively. Histopathological examination showed no significant decrease in PCO.
  
  
  CONCLUSIONS
  Although sustained release of indomethacin significantly decreased inflammation, it did not reduce PCO.
authors.affiliation: Nishi Eye Hospital, Osaka, Japan.
authors.forename: O
authors.initials: O
authors.lastname: Nishi
authors.forename: K
authors.initials: K
authors.lastname: Nishi
authors.forename: T
authors.initials: T
authors.lastname: Morita
authors.forename: Y
authors.initials: Y
authors.lastname: Tada
authors.forename: E
authors.initials: E
authors.lastname: Shirasawa
authors.forename: K
authors.initials: K
authors.lastname: Sakanishi
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use; D001082:Aqueous Humor / Q000166:cytology / Q000378:metabolism; D001672:Biocompatible Materials; D002386:Cataract / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D002387:Cataract Extraction / Q000009:adverse effects; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D015232:Dinoprostone / Q000378:metabolism; D009877:Endophthalmitis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005500:Follow-Up Studies; D007213:Indomethacin / Q000008:administration & dosage* / Q000627:therapeutic use; D019344:Lactic Acid; D007903:Lens Capsule, Crystalline / Q000187:drug effects* / Q000473:pathology; D007910:Lenses, Intraocular / Q000009:adverse effects; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011817:Rabbits; D011863:Radioimmunoassay
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D015232:Dinoprostone; D007213:Indomethacin